Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study

Highlights • The next-day residual effects of zolpidem, triazolam, and rilmazafone were evaluated. • Zolpidem 5 mg and triazolam 0.125 mg did not have next-day residual effects. • Rilmazafone 1 mg exhibited steadiness in static and dynamic balance. • Residual effects appear to be related to the comp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Sleep medicine 2015-11, Vol.16 (11), p.1395-1402
Hauptverfasser:	Uemura, Sachiko Ito, Kanbayashi, Takashi, Wakasa, Masahiko, Satake, Masahiro, Ito, Wakako, Shimizu, Kazumi, Shioya, Takanobu, Shimizu, Tetsuo, Nishino, Seiji
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Cross-Over Studies Double-Blind Method Elderly Female Healthy Volunteers Humans Hypnotics and Sedatives - pharmacokinetics Hypnotics and Sedatives - pharmacology Male Middle Aged Neurology Psychomotor Performance - drug effects Pyridines - pharmacokinetics Pyridines - pharmacology Randomized study Residual effects Rilmazafone Sleep Medicine Triazolam Triazolam - pharmacokinetics Triazolam - pharmacology Triazoles - pharmacokinetics Triazoles - pharmacology Zolpidem
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The next-day residual effects of zolpidem, triazolam, and rilmazafone were evaluated. • Zolpidem 5 mg and triazolam 0.125 mg did not have next-day residual effects. • Rilmazafone 1 mg exhibited steadiness in static and dynamic balance. • Residual effects appear to be related to the compound's half-life and the dose used.
ISSN:	1389-9457 1878-5506
DOI:	10.1016/j.sleep.2015.05.021